ArticleFrontiers in bioinformatics2026
Revealing RELL1 signaling relying on the phosphoregulatory network analysis.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: RELL1 (Receptor Expressed in Lymphoid Tissues-Like 1) is a member of the TNF receptor superfamily. Although the physiological ligands and mechanistic insights into cell signaling still remain to be elucidated, its over-expression is associated with poor prognosis and enhanced immune cell infiltration in cancers, marking it a potential oncogenic driver and immunotherapeutic target. Despite extensive phosphoproteomic evidence indicating that RELL1 undergoes phosphorylation, the functional significance of its phosphosites has not been systematically investigated. Methods: Global human phosphoproteomic datasets were systematically analyzed to identify predominant RELL1 phosphosites. The two most frequently detected phosphosites were selected as predominant sites for phosphosite-centric analysis. To explore their functional significance, their highly co-phosphoregulated sites in other proteins across diverse conditions were examined. A stringent criteria was applied to determine protein phosphosites that showed either positive or negative co-regulation with predominant sites. These co-regulated sites were further analyzed within known interacting proteins, and predicted the upstream regulators of RELL1, followed by enrichment analysis. Results: Exemplified by the detection of its phosphorylated forms in 474 qualitative and 150 quantitative phosphoproteomic datasets across multiple experimental conditions, we propose phosphorylation as a potential regulatory mechanism associated with RELL1 function. However, the functional role of any of the phosphosites in RELL1 phosphosites remains unknown. Among the detected phosphosites, S244 and S161 were the most frequently observed sites perturbed across datasets, and hence, considerably the predominant sites. Co-phosphoregulation analysis revealed plausible regulatory networks comprising interacting proteins and predicted upstream kinases. Bioinformatics analyses revealed strong associations between these phosphosites and biological processes such as nuclear transport and cell cycle regulation. Conclusion: This systems-level phosphoproteomic investigation provides the potential phosphoregulatory map for RELL1 phosphosites, which could lay a foundation for further experimental investigations as well as in establishing its functional roles contributing to advancements in RELL1 signaling events relevant to immuno-oncotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.